



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

July 11, 2013

FILE COPY

Joan Janulis, R.A.C.
Vice President
Lachman Consultant Services, Inc.
1600 Stewart Avenue
Westbury, NY 11590

Dear Ms. Janulis:

Your petition to the Food and Drug Administration requesting to declare that the drug product, Tizanidine Hydrochloride Tablets, 8 mg, is suitable for consideration in an abbreviated new drug application (ANDA), was received by this office on 07/11/2013. It was assigned docket number FDA-2013-P-0847/CP1, and it was filed on 07/11/2013. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

A handwritten signature in cursive script, reading "Gloria Ortega", is positioned above the printed name.

Gloria Ortega
Administrative Proceedings Officer
Division of Dockets Management
FDA/Office of the Executive Secretariat (OES)